178 related articles for article (PubMed ID: 32829664)
1. Nitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy.
Ataei Ataabadi E; Golshiri K; Jüttner A; Krenning G; Danser AHJ; Roks AJM
Hypertension; 2020 Oct; 76(4):1055-1068. PubMed ID: 32829664
[TBL] [Abstract][Full Text] [Related]
2. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
3. Conventional and Unconventional Mechanisms for Soluble Guanylyl Cyclase Signaling.
Gao Y
J Cardiovasc Pharmacol; 2016 May; 67(5):367-72. PubMed ID: 26452163
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation.
Jüttner AA; Danser AHJ; Roks AJM
Adv Pharmacol; 2022; 94():57-94. PubMed ID: 35659377
[TBL] [Abstract][Full Text] [Related]
5. A primer for measuring cGMP signaling and cGMP-mediated vascular relaxation.
Straub AC; Beuve A
Nitric Oxide; 2021 Dec; 117():40-45. PubMed ID: 34601102
[TBL] [Abstract][Full Text] [Related]
6. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Mónica FZ; Bian K; Murad F
Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
[TBL] [Abstract][Full Text] [Related]
7. Paracrine nitric oxide induces expression of cardiac sarcomeric proteins in adult progenitor cells through soluble guanylyl cyclase/cyclic-guanosine monophosphate and Wnt/β-catenin inhibition.
De Pauw A; Massion P; Sekkali B; Andre E; Dubroca C; Kmecova J; Bouzin C; Friart A; Sibille C; Gilon P; De Mulder D; Esfahani H; Strapart A; Martherus R; Payen V; Sonveaux P; Brouckaert P; Janssens S; Balligand JL
Cardiovasc Res; 2016 Oct; 112(1):478-90. PubMed ID: 27520736
[TBL] [Abstract][Full Text] [Related]
8. [Nitric Oxide Signaling Pathway and Vascular Activity].
Gao YS
Sheng Li Ke Xue Jin Zhan; 2017 Feb; 48(1):58-62. PubMed ID: 29927223
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
10. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
11. A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug.
Chrysant SG
Expert Opin Drug Saf; 2021 Jun; 20(6):635-640. PubMed ID: 33734912
[TBL] [Abstract][Full Text] [Related]
12. Changes in the nitric oxide-soluble guanylate cyclase system and natriuretic peptide receptor system in placentas of pregnant Dahl salt-sensitive rats.
Takushima S; Nishi Y; Nonoshita A; Mifune H; Hirata R; Tanaka E; Doi R; Hori D; Kamura T; Ushijima K
J Obstet Gynaecol Res; 2015 Apr; 41(4):540-50. PubMed ID: 25370989
[TBL] [Abstract][Full Text] [Related]
13. Activation of nitric oxide/cGMP/PKG signaling cascade mediates antihypertensive effects of Muntingia calabura in anesthetized spontaneously hypertensive rats.
Shih CD
Am J Chin Med; 2009; 37(6):1045-58. PubMed ID: 19938215
[TBL] [Abstract][Full Text] [Related]
14. The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase.
Golshiri K; Ataei Ataabadi E; Portilla Fernandez EC; Jan Danser AH; Roks AJM
Basic Clin Pharmacol Toxicol; 2020 Aug; 127(2):67-80. PubMed ID: 31495057
[TBL] [Abstract][Full Text] [Related]
15. Identification of downstream target genes regulated by the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signal pathway in pulmonary hypertension.
Zou L; Xu X; Zhai Z; Yang T; Jin J; Xiao F; Wang C
J Int Med Res; 2016 Jun; 44(3):508-19. PubMed ID: 27048385
[TBL] [Abstract][Full Text] [Related]
16. Intrauterine growth restriction is associated with sex-specific alterations in the nitric oxide/cyclic GMP relaxing pathway in the human umbilical vein.
Beaumann M; Delhaes F; Menétrey S; Joye S; Vial Y; Baud D; Magaly JG; Tolsa JF; Peyter AC
Placenta; 2020 Apr; 93():83-93. PubMed ID: 32250743
[TBL] [Abstract][Full Text] [Related]
17. Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology.
Patel D; Lakhkar A; Wolin MS
Adv Exp Med Biol; 2017; 967():227-240. PubMed ID: 29047089
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Frankenreiter S; Groneberg D; Kuret A; Krieg T; Ruth P; Friebe A; Lukowski R
Cardiovasc Res; 2018 May; 114(6):822-829. PubMed ID: 29438488
[TBL] [Abstract][Full Text] [Related]
19. Endurance training upregulates the nitric oxide/soluble guanylyl cyclase/cyclic guanosine 3',5'-monophosphate pathway in the striatum, midbrain and cerebellum of male rats.
Chalimoniuk M; Chrapusta SJ; Lukačova N; Langfort J
Brain Res; 2015 Aug; 1618():29-40. PubMed ID: 26006108
[TBL] [Abstract][Full Text] [Related]
20. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
Sandner P; Berger P; Zenzmaier C
Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
